Busy Day for MannKind

Development-stage drugmaker and Motley Fool Hidden Gems Pay Dirt pick MannKind (Nasdaq: MNKD  ) had a busy day the other day. The announcements: results from one of several phase 3 studies for its inhaled insulin diabetes treatment Technosphere, a new partnership of sorts with Pfizer (NYSE: PFE  ) , and the brand name of Afresa for Technosphere if it's approved for marketing.

For any diabetes treatment, the gold standard for measuring a compound's effectiveness is how well it works to lower a patient's long-term blood sugar level (what are known as HbA1c levels). In this one-year study, Technosphere performed at least equally as well at controlling diabetics' blood sugar levels as long-approved insulin treatment Novolog from Novo Nordisk (NYSE: NVO  ) . No matter how you slice the data about its effectiveness, Technosphere succeeded. That's good news.

Even more important considering what happened earlier this year, MannKind didn't report any lung neoplasms (tumors, benign or not) in the study. This is the suspected adverse event that affected Exubera -- Nektar Therapeutics (Nasdaq: NKTR  ) and Pfizer's inhaled insulin product -- last spring. Many worry that this effect could be part of all inhaled insulins. While it's good news that MannKind didn't report any neoplasms in this study, a significantly larger and longer clinical trial is probably needed to tease out any possible relationship or lack of relationship between Technosphere and a rarely occurring issue such as lung neoplasms.

Overall, though, this study can be considered a success on the efficacy side. It is only the first of three phase 3 trials for which MannKind will be announcing data over the coming months. MannKind still expects to file a marketing application for Technosphere with the FDA late this year or early next year, so investors won't have to wait much longer for the rest of the pivotal phase 3 data to come in.

It's hoped a clearer picture of Technosphere's safety profile will emerge by the end of the year. That will make or break the whole deal.

MannKind is a Motley Fool Hidden Gems Pay Dirt pick. Pfizer is an Inside Value and an Income Investor pick. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 731177, ~/Articles/ArticleHandler.aspx, 10/23/2014 1:30:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASD 4,382.85 -36.63 -0.83%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/22/2014 4:00 PM
MNKD $5.39 Down -0.14 -2.53%
MannKind Corp CAPS Rating: ***
NKTR $12.67 Up +0.03 +0.24%
Nektar Therapeutic… CAPS Rating: **
NVO $45.34 Down -0.09 -0.20%
Novo Nordisk CAPS Rating: *****
PFE $28.30 Up +0.02 +0.07%
Pfizer CAPS Rating: ****

Advertisement